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Abstract
Background: Increasingly, countries have introduced female vaccination against human papillomavirus (HPV), causally
linked to several cancers and genital warts, but few have recommended vaccination of boys. Declining vaccine prices and
strong evidence of vaccine impact on reducing HPV-related conditions in both women and men prompt countries to
reevaluate whether HPV vaccination of boys is warranted.
Methods: A previously-published dynamic model of HPV transmission was empirically calibrated to Norway. Reductions in
the incidence of HPV, including both direct and indirect benefits, were applied to a natural history model of cervical cancer,
and to incidence-based models for other non-cervical HPV-related diseases. We calculated the health outcomes and costs of
the different HPV-related conditions under a gender-neutral vaccination program compared to a female-only program.
Results: Vaccine price had a decisive impact on results. For example, assuming 71% coverage, high vaccine efficacy and a
reasonable vaccine tender price of $75 per dose, we found vaccinating both girls and boys fell below a commonly cited
cost-effectiveness threshold in Norway ($83,000/quality-adjusted life year (QALY) gained) when including vaccine benefit for
all HPV-related diseases. However, at the current market price, including boys would not be considered ‘good value for
money.’ For settings with a lower cost-effectiveness threshold ($30,000/QALY), it would not be considered cost-effective to
expand the current program to include boys, unless the vaccine price was less than $36/dose. Increasing vaccination
coverage to 90% among girls was more effective and less costly than the benefits achieved by vaccinating both genders
with 71% coverage.
Conclusions: At the anticipated tender price, expanding the HPV vaccination program to boys may be cost-effective and
may warrant a change in the current female-only vaccination policy in Norway. However, increasing coverage in girls is
uniformly more effective and cost-effective than expanding vaccination coverage to boys and should be considered a
priority.
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Introduction
Persistent infection with human papillomavirus (HPV), a known
causal agent for cervical cancer, is emerging as an important risk
factor for several diseases in both women and men. High-risk,
oncogenic HPV infections, most importantly HPV-16 and to a
lesser extent HPV-18, are responsible for a proportion of vulva,
vaginal, anal, penile and oropharygeal cancers (Figure 1).
Infection with low-risk HPV, most notably HPV-6 and -11, are
responsible for the majority of genital warts and recurrent
respiratory papillomatosis (RRP).
In Norway, a 3-dose schedule of the quadrivalent HPV vaccine,
shown to have high efficacy against HPV-16, -18, -6, and -11, has
been offered to pre-adolescent girls through school-based delivery
in the 7th grade since 2009. The most recent cohort of girls (born
in 1999) has achieved 2- and 3-dose coverage rates of 79% and
71%, respectively [1]. Worldwide, a growing number of countries
recommend or permit HPV vaccination for males aged 9–26,
PLOS ONE | www.plosone.org 1 March 2014 | Volume 9 | Issue 3 | e89974though few have offered to publicly fund the policy [2]. Given the
highly transmissible nature of HPV through sexual activity, high
vaccination coverage among pre-adolescent girls may provide a
high level of indirect benefit to boys, effectively reducing the
burden of HPV-related disease in both sexes [3]. Ecological data
from Australia and the U.S. support this finding [4,5]. Generally,
cost-effectiveness analyses evaluating HPV vaccine introduction in
several countries have concluded that the incremental benefit of
expanding HPV vaccination programs to include pre-adolescent
boys may not justify the added cost, particularly if vaccination
coverage among girls is high [6–8]. One of the most influential
parameters in such analyses is vaccine price. In Norway, the
market price is roughly $150 per dose; however, pharmaceutical
statistics from Norway in 2011–2012 indicate that the nationally-
negotiated tender may be half of the market price (i.e.,
approximately $75 per dose [9]). It is conceivable that future
negotiations may continue to press the vaccine price down.
In light of declining vaccine prices and the growing evidence of
vaccine impact on reducing multiple HPV-related conditions in
both women and men [10], countries such as Norway must assess
whether including boys in the publicly funded childhood
vaccination program is warranted. In addition, alternate dosing
schedules (i.e., two versus three doses) may further reduce the cost
per vaccinated individual without decreasing efficacy [11]. A
comprehensive analysis across a broad range of vaccine prices for
developed countries has not been undertaken. In addition,
evaluating the value of expanding the Norwegian HPV vaccina-
tion program to include boys has not been conducted but is
essential for guiding setting-specific health care policy and is
required inter alia for priority-setting in Norway [12]. We aim to
assess whether HPV vaccination of pre-adolescent boys is a cost-
effective use of finite resources by explicitly considering HPV
transmission dynamics, including a wide range of HPV-related
conditions, and exploring the impact of different vaccine tender
prices.
Methods
Decision analytic approach
We adapted a dynamic model of HPV sexual transmission and
multiple disease simulation models to reflect the health and
economic burden of HPV-related conditions in Norway across
multiple birth cohorts of men and women [7,13]. We compared
the current HPV vaccination program that targets only 12-year-
old girls to an expanded program that includes 12-year-old boys.
The analysis included outcomes related to the HPV types targeted
by the quadrivalent vaccine, including carcinogenic types 16 and
18 and non-carcinogenic types 6 and 11. We simulated the female
vaccination program starting in 2009, while male vaccination was
assumed to be implemented in 2014; to isolate the impact of
vaccinating boys, the costs and benefits for the first five years of the
female-only program were not counted. Taking into consideration
all HPV-related conditions, we projected long term outcomes
across the entire lifetime of the first 30 male and female cohorts
under a gender-neutral vaccination program compared to a
female-only program. Monetary costs were measured in 2010
Norwegian Kroner (NOK) and converted to US dollars using the
average annual 2010 exchange rate ($1=NOK6.05) [14]. We
adopted a societal perspective and discounted costs and health
benefits by 4% per year over the lifetime of each simulated cohort,
consistent with Norwegian guidelines [15]. We assessed cost-
effectiveness by calculating the incremental cost-effectiveness ratio
(ICER), defined as the additional cost divided by the additional
quality-adjusted life year (QALY) gained associated with one
strategy compared to the next less costly strategy. We used a
commonly cited Norwegian threshold of NOK500,000 per QALY
gained (<$83,000) to represent a ‘‘cost-effective’’ intervention
[16], but also considered alternative thresholds ($30,000–$100,000
per QALY) to reflect the lack of consensus for a single threshold
value in Norway
15 and a range of threshold values cited in other
settings.
Figure 1. Proportion of human papillomavirus (HPV)-16 and -18 related cancers in Norway, by gender. For oropharyngeal cancers, we
considered three sub-sites: 1) oropharynx, 2) base of tongue and 3) tonsils. For all other cancers, we considered all histologies reported at each sub-
site. Percentages have been rounded to the nearest whole number.
doi:10.1371/journal.pone.0089974.g001
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HPV-related conditions (ICD-10 code) Women Men Setting
Anal cancer (C21)
Incidence per 100,000, mean (range)
a 1.9 (0–9.1) 0.9 (0–5.7) Norway [21]
5-year relative survival (%)
b 70.4 51.3 Norway [21]
Quality of life adjustment
c 0.57 Australia [26]
Cases attributable to HPV-16 (%) 73 N. Europe [23]
Cases attributable to HPV-18 (%) 9 N. Europe [23]
Cost per case ($)
d 37,500 Norway
d
Cervical cancer (C53)
Incidence per 100,000, mean (range)
a 24.0 (0–32.0) – Norway [21]
5-year relative survival (%)
b 19.9–91.0 – Norway [21]
Quality of life adjustment
c 0.48–0.76 – US [25]
Cases attributable to HPV-16 (%) 56 – Norway [32]
Cases attributable to HPV-18 (%) 16 – Norway [32]
Cost per case ($)
d 25,800–59,600 – Norway
d
Oropharyngeal-related (C01,09,10)
Incidence per 100,000, mean (range)
a 1.5 (0–6.5) 3.8 (0–14.1) Norway [21]
5-year relative survival (%)
b 57.6 60.3 Norway [21]
Quality of life adjustment
c 0.58 Australia [26]
Cases attributable to HPV-16, -18 (%) 53 Norway [24]
Cases attributable to HPV-16, -18 (%) 1 Norway [24]
Cost per case ($)
d 49,000 Norway
d
Penile cancer (C60)
Incidence per 100,000, mean (range)
a – 2.0 (0–11.4) Norway [21]
5-year relative survival (%)
b – 81 Norway [21]
Quality of life adjustment
c – 0.79 Australia [26]
Cases attributable to HPV-16 (%) – 42 N. Europe [23]
Cases attributable to HPV-18 (%) – 4 N. Europe [23]
Cost per case ($)
d – 17,500 Norway
d
Vaginal cancer (C52)
Incidence per 100,000, mean (range)
a 0.6 (0–4.3) – Norway [21]
5-year relative survival (%)
b 48.6 – Norway [21]
Quality of life adjustment
c 0.59 – Australia [26]
Cases attributable to HPV-16 (%) 63 – N. Europe [23]
Cases attributable to HPV-18 (%) 3 – N. Europe [23]
Cost per case ($)
d 26,400 – Norway
d
Vulvar cancer (C51)
Incidence per 100,000, mean (range)
a 3.4 (0–26.5) – Norway [21]
5-year relative survival (%)
b 72.8 – Norway [21]
Quality of life adjustment
c 0.65 – Australia [26]
Cases attributable to HPV-16 (%) 38 – N. Europe [23]
Cases attributable to HPV-18 (%) 6 – N. Europe [23]
Cost per case ($)
d 27,900 – Norway
d
Non-cancer HPV related conditions
Genital warts
Incidence per 1,000, (age-specific range) 0.02–7.14 0.01–8.85 Sweden [33], UK [34]
Quality of life adjustment
c 0.9277 UK [31]
Cases attributable to HPV-6, -11 (%) 90 Multiple [35,36]
Cost per case ($)
d 400 Norway
d
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We refined a previously-developed dynamic model of HPV-16
and -18 transmission [7,13] to simulate heterosexual behavior
between men and women in Norway and an individual-based
disease model [17] to simulate HPV-induced cervical cancer in the
context of the current Norwegian screening program. For all non-
cervical HPV-related conditions, we used an incidence-based
modeling approach to capture the health and economic burdens in
both genders.
The dynamic model is age-structured in yearly intervals and
simulates multiple birth cohorts over their lifetimes. Individuals are
designated into one of four sexual activity groups (i.e., none, low,
moderate, high), which governs the rate of partner change per
year and varies by age and gender, based on data from two
Norwegian sexual behavior surveys [18,19]. HPV transmission
occurs as a function of the number of new partners, prevalence of
HPV in the opposite gender, and HPV-type and gender-specific
probabilities of transmission from an infected partner to an
uninfected partner. We assumed that male-to-female transmission
was 0.80 times as much as female-to-male transmission estimated
from an empirical study [20]. After clearance from an initial HPV
infection, partial gender- and type-specific immunity develops,
reducing future rates of acquiring the same type of HPV.
The individual-based stochastic model, previously adapted to
the Norwegian context [17], mimics the natural history of cervical
cancer and allows for complex screening algorithms to be
simulated. Individual girls enter the model and face age-specific
monthly probabilities of acquiring HPV, categorized as 16, 18,
other high-risk or low-risk types. Individuals can develop
precancerous lesions, which may regress naturally, or progress to
invasive cervical cancer. Survival from cervical cancer was
estimated from the Cancer Registry of Norway and varied based
on stage of detection [21].
Initial parameters for both models were based on data from
epidemiological and demographic studies [7,13,22]. We calibrated
the models using a likelihood-based method to fit empirical
outcomes observed in Norway, such as HPV prevalence and
cervical cancer incidence. Additional explanation of the Norwe-
gian-specific calibration process can be found in (File S1). The
natural history of HPV-related non-cervical conditions is not well
known; therefore, we elected to develop simplified models
simulating the disease incidence rates by age and gender [21]
and attributable fraction of vaccine-targeted HPV types for each of
these conditions [23,24]. We used the transmission model to
project the reductions in vaccine-type HPV incidence attributable
to vaccination, including both direct and indirect protection (i.e.,
herd immunity). These reductions in HPV infections were used as
inputs into the disease simulation models to then project the
corresponding reductions in related diseases. For all models,
individuals faced all-cause mortality at each time step, and when
applicable, excess mortality after disease onset.
Costs
Baseline costs associated with HPV vaccination included costs
for all three vaccine doses using the estimated tender price of $75
per dose [9], wastage and supplies. We assumed that 10% [1] of
those who initiate vaccine do not complete all three doses, thereby
incurring some vaccine costs but no vaccine benefit; however, we
examined alternative benefit assumptions in sensitivity analysis.
Estimation of costs associated with cervical cancer screening,
diagnosis, and treatment is documented in a previous cost-
effectiveness analysis [17]. Norwegian-specific treatment costs
associated with the other non-cervical HPV-related conditions
included all direct medical and nonmedical costs associated with
diagnosis, treatment and post-treatment surveillance, if applicable
(Table 1). Future costs and benefits for juvenile-onset RRP were
discounted to the time of vaccination of the mother. See (File S1)
for further explanation of costing methods.
Health-related quality of life
Health state utility weights for cervical cancer varied according
to stage (Table 1) [25]. For non-cervical cancers, we opted to use
a study that elicited utility values for multiple non-cervical cancers
simultaneously. Valuations were elicited using standard gamble
from the general population in Australia [26]. In Norway, the
long-term impact after surviving a gynecological cancer (average
Table 1. Cont.
HPV-related conditions (ICD-10 code) Women Men Setting
Juvenile recurrent respiratory papillomatosis
Incidence per 100,000 0.17 Norway [37]
Quality of life adjustment
c 0.69 US [30]
Cases attributable to HPV-6, -11 (%) 100 Multiple [35]
Cost per case ($)
d 133,800 Norway
d
HPV: human papillomavirus,
aMean incidence reported for 2008–2010 for all HPV-related cancers except cervical cancer. Variation represents range in age-specific rates. Invasive cervical cancer
incidence (used for calibration) is reported based on the pre-screening (1953–1969) mean of the minimum and maximum annual incidence from Norwegian Cancer
Registry.
b5-year relative survival is reported for calendar-period observation for 2006–2010; for cervical, the range represents stage-specific estimates for local (91%), regional
(66%), and distant (19.9%).
cQuality of life adjustment range from a health state utility weight of 0 (death) to 1 (perfect health). Weights for cervical cancer varied according to stage (local: 0.76 for
five years; regional: 0.67 for five years; distant: 0.48 five years). Utility weights for other non-cervical HPV-related cancers are applied for five years. For genital warts, a
mean quality of life loss of 6.6. days is assumed [32], which is approximately a utility weight of 0.9277 over three months; for recurrent respiratory papillomatosis, health
state utility weight of 0.68 over four years is assumed. Disease specific utility weights were multiplied to baseline age-specific utility weights [29] to estimate overall
utility.
dCost per case is expressed in 2010 US dollars (1 USD=6.05 Norwegian Kroner) and represent discounted (4% per year) costs for diagnosis and 5-year follow-up
inclusive of direct (procedures, inpatient stays, general practitioner visits) and non-direct medical costs (transport) and patient time. The proportion of direct non-
medical costs for all non-cervical conditions was estimated from cervical cancer (15%) and applied to baseline direct medical costs. Treatment of cervical cancer varies
according to stage of detection (local: $25,800; regional: $51,600; distant: $59,600). See (File S1) for estimation methods.
doi:10.1371/journal.pone.0089974.t001
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general public [27]. Furthermore, a Danish study that followed
women with advanced stage cervical cancer found that quality of
life among women 18-months post radiation treatment was
comparable to the general population [28]. Based on these data,
we conservatively assumed that individuals with detected cancer
remained in a state of reduced quality of life for five years, after
which individuals returned to their gender- and age-specific utility
values elicited from the general population in a neighboring
Scandinavian country [29]. For HPV-6 and -11 related conditions,
we applied disease-specific utility values for the average duration of
the disease (i.e., 3-months for genital warts and 4.2 years for RRP)
[30,31].
Other model inputs
We synthesized available data from Norway, or from surround-
ing countries when Norwegian-specific data were not available, to
inform parameter inputs, such as disease incidence, survival and
cases attributable to vaccine-targeted HPV types (Table 1). Our
base case assumed vaccine efficacy against disease outcomes
related to vaccine-targeted HPV types of 100% for females and
90% for males over the lifetime, in line with a recent systematic
review [10]. Additional information may be obtained from the
authors upon request.
Analysis
We compared a scenario of routine HPV vaccination of 12-
year-old girls only at the current Norwegian 3-dose coverage level
(71%) to a scenario that assumes similar coverage is achieved by
12-year-old boys. We calculated the health outcomes and costs of
the different HPV-related conditions and explored the impact of
different vaccine prices ranging from $20–$160 per dose. We
evaluated the impact of model assumptions on cost-effectiveness
using one- and multi-way sensitivity analysis. For one-way
sensitivity analysis, we varied vaccine efficacy, duration, incidence
of oropharyngeal cancer and considered an alternate vaccine dose
schedule (assuming two doses confer the same vaccine protection
as three doses). To provide an approximate estimate of the impact
of the men who have sex with men (MSM) population on results,
we systematically reduced the herd immunity benefits conferred to
the male-population in the female-only vaccination strategy. For
the multi-way sensitivity analysis, we simultaneously varied
treatment costs and the attributable fraction of HPV-16 and -18
in each HPV-related condition to determine ‘‘optimistic’’ and
‘‘pessimistic’’ results. We also varied analytic assumptions, such as
the discount rate (0% and 3%) and consideration of direct costs
only, consistent with Norwegian guidelines [15]. Lastly, we
considered a third scenario which involved increasing the coverage
rate among pre-adolescent girls to 90%, the level currently
achieved by the measles, mumps, rubella (MMR) vaccine
administered to pre-adolescent Norwegians aged 11–12. Expand-
ing HPV vaccination coverage for girls was directly compared to
extending coverage to boys in order to determine which strategy
minimizes the burden of HPV-related conditions in Norway at a
reasonable cost.
Results
Epidemiological outcomes
Assuming the current 3-dose vaccination coverage rate among
pre-adolescent girls remains constant at 71% with 100% lifelong
efficacy, the girls-only vaccination program was projected to
substantially reduce future cancer incidence (Table 2). The
additional reductions in cancer incidence by adding male
vaccination (assuming equal coverage) were modest. We project
that, for the same future cohort, female genital warts may decrease
by 77% and male genital warts may decrease by 62%, under a
female-only vaccination program. For a gender-neutral vaccina-
tion program, reductions in genital warts may increase to 85% and
84% among females and males, respectively.
Cost-effectiveness
At the assumed tender price of $75 per dose, the cost per QALY
gained from routine vaccination of girls only (compared to no
vaccination) was $20,600 when including only benefits related to
cervical outcomes and $5,000 when including benefits associated
Table 2. Projected reductions in HPV-related cancer incidence, by gender.
No vaccination Girls-only vaccination
b Girls + boys vaccination
b
Disease, 2008–2010
a Incidence rate
Change in incidence rate compared
to no vaccination (% reduction)
Change in incidence rate compared to
girls vaccination (% reduction)
Female
Cervical
c 12.6 25.2 (41%) 20.8 (10%)
Vulvar 3.4 21.2 (36%) 20.1 (6%)
Vaginal 0.6 20.3 (54%) 20.03 (11%)
Anal 1.9 21.3 (67%) 20.1 (21%)
Oropharyngeal 1.5 20.6 (43%) 20.1 (9%)
Male
Penile 2.0 20.6 (29%) 20.3 (18%)
Anal 0.9 20.5 (52%) 20.2 (46%)
Oropharyngeal 3.8 21.0 (33%) 20.6 (22%)
aAge-standardised incidence rates are expressed as 100,000 per individual and have not been adjusted for world population; rates under no vaccination scenario refer
to current rates reported from the Cancer Registry of Norway [21]
bProjections reflect the expected cancer reduction estimated from the dynamic transmission model for the last cohort to be vaccinated in this analysis. See Methods
section for assumptions regarding vaccine efficacy against non-cervical cancers.
cProjected reduction in risk of cervical cancer is estimated from the stochastic disease model and in the context of current cervical cancer screening compliance.
doi:10.1371/journal.pone.0089974.t002
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Expanding the vaccination program to include pre-adolescent
boys, assuming the same 3-dose coverage rate and 90% lifelong
vaccine efficacy in males, the cost per QALY gained was $145,500
accounting for cervical cancer outcomes only, but fell to $60,100
per QALY gained when including all HPV-related outcomes. The
incremental cost-effectiveness ratios of vaccinating both genders
compared to vaccinating girls only over a wide range of vaccine
prices is shown in Figure 2. Accounting for all HPV-related
outcomes, expanding HPV vaccination to boys would be
considered cost-effective at a vaccine cost per dose of approxi-
mately $101, $62 and $36 for willingness-to-pay thresholds of
$83,000, $50,000 and $30,000 per QALY gained, respectively.
Therefore, at the current market price, expanding the current
HPV vaccination program to include boys would not be
considered ‘good value for money.’ When restricting vaccine
benefit to only cancers (i.e., no genital warts or RRP), the vaccine
cost per dose would have to be at least 30% lower for male
vaccination to be considered cost-effective, compared to girls-only
vaccination.
Sensitivity analysis
The impact of model assumptions on the incremental cost-
effectiveness ratio of a gender-neutral vaccine program compared
to a girls-only program (including outcomes related to all HPV-
related conditions) for three vaccine prices is shown in Table 4.
The incremental cost-effectiveness ratios associated with including
boys in the vaccination program (at $75 per dose) begin to exceed
a threshold of $83,000 per QALY either when the cost-
effectiveness results were expressed in terms of life years (not
QALY) gained or when the lower bound of the disease-specific
HPV-16 and -18 attributable fractions and lower disease treatment
costs (‘‘pessimistic scenario’’) were assumed simultaneously. At the
market price of the vaccine ($150 per dose), vaccination of both
genders was never cost-effective across key parameter variations
given a threshold of $83,000 per QALY gained. The incremental
cost-effectiveness ratio only fell below $100,000 per QALY gained
when we considered the benefit and costs associated with a 2-dose
vaccination schedule or lower discount rates. At $50 per dose, the
ratios generally remained above $30,000 per QALY gained. For a
vaccine price of $75 per dose, we found that the cost per QALY
gained fell below $50,000 only when the herd immunity benefits
conferred to the male-population in the girls-only vaccination
program was reduced by more than 15% (i.e., assuming the
female-only HPV vaccination program produced smaller herd
immunity benefits due to the MSM population). When we doubled
the incidence of oropharyngeal cancer in both genders, we found
that the incremental cost-effectiveness ratios of vaccinating boys
fell by approximately 15–17%, depending on the cost per dose of
the vaccine.
Apart from vaccine price, the discount rate and increasing
vaccination coverage in pre-adolescent girls had the most influence
Figure 2. Incremental cost effectiveness ratios (ICER) of vaccinating pre-adolescent girls and boys compared to vaccinating pre-
adolescent girls only. Shaded area represents the broad range of willingness-to-pay thresholds ($30,000–$100,000 per QALY gained) accepted
across developed countries. Dotted line represents a threshold often cited in Norway ($83,000 per QALY gained).
16 Cost per dose excludes the
administration cost (<$14 per dose).
doi:10.1371/journal.pone.0089974.g002
Table 3. Incremental cost-effectiveness ratios of including
pre-adolescent boys in the childhood vaccination program
compared to vaccination of pre-adolescent girls only.
Vaccination strategy
a
HPV-related outcome(s) included Girls only
b Girls + boys
c
Cervix only $20,600 $145,500
Female cancers
d $12,800 $119,300
Female + male cancers
e $8,900 $81,700
All HPV-related conditions
f $5,000 $60,100
aAssumes a cost per dose of $75, exclusive of the administration cost (<$14 per
dose).
bCompared to no vaccination.
cCompared to girls-only vaccination.
dIncludes female cervical, vulvar, vaginal, anal and oropharyngeal cancers,
eIncludes male anal, oropharyngeal and penile cancers,
fIncludes cervical, vulvar, vaginal, anal, oropharyngeal and penile cancers
related to HPV-16, -18, and genital warts and recurrent respiratory
papillomatosis related to HPV-6, -11.
doi:10.1371/journal.pone.0089974.t003
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alone to 90% was more effective and less costly, and therefore
dominated, a scenario of vaccinating both genders with 71%
coverage. We calculated that more than twice the amount per
vaccinated girl – or six times the amount, if the funds were
targeted specifically to those who did not previously uptake – could
be spent before adding boys to the vaccination program would be
equally cost-effective as increasing participation among girls only.
Although extending HPV vaccination to boys provides benefits to
both genders, increasing coverage within a girls-only program
prevents more HPV-16,-18 related female cancers than a gender-
neutral program that achieves 71% coverage. Through additional
herd immunity benefits, increasing female-only vaccine uptake can
prevent nearly as many HPV-related cancers among men as by
vaccinating boys directly (Figure 3). Even if increasing coverage
among girls did not provide any additional herd immunity benefits
to the boys, the scenario still provided greater overall reductions in
cancer cases than vaccinating both genders (see Table S9 in File
S1).
Discussion
Our findings confirm that vaccine price is one of the most
influential parameters when determining cost-effectiveness of
extending the current female-only HPV vaccination program to
include boys. In order to aid policy decisions in settings where
stakeholders are privy to the national tenders procured at a lower
price per dose than the publicly available price, we express the
incremental cost-effectiveness ratios across a range of plausible
vaccine prices. Our analysis suggests that there may be some
combinations of vaccine price and willingness-to-pay thresholds
where adding boys is cost-effective, even when current 3-dose
coverage rates are already high (i.e., 70% among girls).
In our base case scenario, which considers a realistic Norwegian
vaccine tender price of $75 per dose, we found that adding 12-
year-old boys to the current HPV vaccination program may be
considered ‘good value for money’ at a willingness-to-pay
threshold of $83,000 per QALY gained. However, the most
recent Norwegian guidelines for economic evaluation emphasize
that consensus surrounding a single Norwegian threshold value
has not been established [15]. In addition, there is support for a
change in screening guidelines for unvaccinated women to a 6-
year interval with primary HPV testing (for women aged 34 years
or older) [38], a strategy estimated at approximately $30,000 for
each additional year of life saved [17]. At this lower willingness-to-
pay threshold, it would not be considered cost-effective to expand
the current program, unless the vaccine price was less than $36 per
dose (Figure 2). At a price of $120 to $150 per dose, expanding
the HPV vaccination program to include boys is unlikely to be
cost-effective even when considering the higher threshold value
($83,000 per QALY gained), a finding that is generally consistent
with other studies [6–8]. Of note, the Norwegian Ministry of
Health has approved cancer medications for reimbursement at
threshold values beyond $83,000 per QALY gained; however, the
total budget impact of these pharmaceuticals is often small as the
targeted health conditions are relatively uncommon [39]. The
same cannot be said for expanding a childhood vaccination policy
to include all boys, which would essentially double the current
HPV vaccination budget.
To our knowledge, there are only three other studies that have
assessed the potential value of adding boys to the pre-adolescent
HPV vaccination program that simultaneously account for HPV
transmission dynamics, consider all HPV-related outcomes, and
report results in terms of cost-effectiveness [6,7,40]. Other studies,
however, have addressed epidemiological endpoints and the
incremental benefit of adding boys to the vaccination program
using static or dynamic models considering one or more HPV-
related outcomes [3,8,29,41–47]. The importance of certain
assumptions for model structure (particularly for transmission
dynamics and non-cervical HPV-related conditions), natural
immunity, coverage and costs have been discussed previously
Table 4. Impact of parameter assumptions on the cost-
effectiveness of including boys in a vaccination program
against human papillomavirus (HPV) (including all HPV-16,-
18,-6,-11 related conditions).
Cost per dose
a
$50 $75 $150
Girls only vaccination (cost per QALY gained)
b
Base case $1,600 $5,000 $14,600
Vaccine duration: 20 yrs $6,500 $12,000 $27,700
Direct medical costs only $2,680 $6,030 $15,650
No disease-specific utilities $5,500 $10,000 $23,000
Discount rate 0% Cost saving Cost saving Cost saving
Discount rate 3% Cost saving $1,600 $7,550
2-dose schedule (79% coverage)
c Cost saving $600 $7,000
Double oropharygeal cancer $800 $3,800 $12,200
Optimistic scenario analysis
d Cost saving $2,100 $10,100
Pessimistic scenario analysis
e $3,100 $6,600 $16,800
Girls + boys vaccination (cost per QALY gained)
f
Base case $40,400 $60,100 $116,700
60% boys coverage $44,400 $65,800 $127,200
80% boys vaccine efficacy $56,100 $82,300 $157,400
Vaccine duration: 20 yrs $38,300 $57,200 $111,400
Direct medical costs only $41,630 $61,370 $118,500
No disease-specific utilities $67,900 $98,500 $186,500
Discount rate 0% $1,490 $4,080 $11,500
Discount rate 3% $23,680 $36,240 $72,300
Increasing girls coverage: 90%
g Dominated Dominated Dominated
2-dose schedule (79% coverage)
c$27,680 $42,320 $84,330
Double oropharygeal cancer $33,300 $50,200 $98,700
Optimistic scenario analysis
d $37,100 $56,300 $111,600
Pessimistic scenario analysis
e $63,100 $91,700 $174,000
QALY: Quality-adjusted life year.
aAll costs are expressed in 2010 US dollars (1US$=NOK6.05) and rounded to the
nearest $10,
bCompared to no vaccination,
cThe 2012 2-dose coverage for girls in Norway is 79%, this scenario assumes
boys achieve the same 2-dose coverage and vaccine efficacy is equal to 3-
doses.
dOptimistic scenario analysis: Upper bound of HPV-16, -18 attributable fraction
and upper bound of treatment cost,
ePessimistic scenario analysis: Lower bound of HPV-16, -18 attributable fraction
and lower bound of treatment costs,
fCompared to girls-only vaccination.
gAssumes HPV vaccination requires 3 doses and girls achieve a similar coverage
as the MMR vaccine (administered age 12–13 years in Norway). Increasing
coverage among girls to 90% was more beneficial and less costly than (i.e.,
dominated) adding boys with 71% coverage.
doi:10.1371/journal.pone.0089974.t004
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rates (20–30%) among girls, adding vaccination of boys becomes
an attractive policy, but if baseline coverage is 75% among girls,
the incremental cost-effectiveness ratio exceeds $100,000 per
QALY gained [6]. This study, however, did not consider the
impact of vaccine price per dose of less than $120. Male HPV
vaccination in Norway may be more attractive than those found in
other settings due to several reason that include (but are not
limited to) the comparatively higher prevalence of HPV-16 and -
18 infections reported in Norway, higher attributable fraction of
HPV-16 and -18 in oropharyngeal cancers [24], the higher
baseline burden of disease (pre-vaccination), and higher Norwe-
gian labor costs that may contribute to higher direct medical and
non-medical treatment costs. In addition, we used health-related
quality of life estimates reported by Conway and colleagues [26]
and with the exception of penile cancer, these estimates are
consistently lower than those reported and used in other studies.
For a specified vaccine price, our findings were generally stable
to variations in critical parameters, with the notable exception of
considering a scenario in which we compared expanding
vaccination to boys versus increasing the coverage rate among
girls, consistent with another study [6]. If feasible, higher uptake in
girls may lead to further reduction in the total burden of HPV-
related diseases, even considering an extreme scenario where
increasing girls’ coverage did not yield any further herd immunity
benefits in males. Another modeling study showed that the most
effective strategy to reduce population prevalence is by optimizing
coverage in a single-sex vaccination program [47]. In addition, the
feasibility of achieving 71% coverage among males, in whom the
disease burden is considerably less than in females (Figure 1), also
requires consideration. On the other hand, overall vaccine
acceptability with a gender-neutral policy may increase without
additional investments, resulting in higher coverage among girls.
When we considered an alternative dosing schedule (using
optimistic assumptions surrounding vaccine duration and efficacy),
we found that a 2-dose regimen resulted in one of the most
appealing strategies for vaccinating boys; however, there is
substantial uncertainty with respect to the duration of protection
from two doses [11]. As expected for programs with large upfront
costs, the discount rate for vaccination programs that avert future
disease was particularly impactful and should be taken into
consideration when interpreting the results of a long-term cost-
effectiveness analysis of preventative programs.
Finally, as both genders are responsible for HPV transmission,
one may argue on equity grounds that both genders should get
vaccinated to share the burden in reducing the risk of HPV-related
disease, as well as have equal access to direct vaccine benefits.
Equity versus efficiency arguments should be considered along-
side the decision-making process and are particularly relevant in
Norway where guidelines explicitly emphasize this trade-off [15].
Limitations
Limitations of our modeling approach have been previously
discussed [7,13], but some deserve particular consideration.
Simplifying assumptions were inherently necessary due to data
limitations or modeling constraints. For example, we assumed that
the burden of HPV-related diseases remain constant over time
while evidence suggests the incidence of oropharyngeal cancer
related to HPV may be increasing [49]. When we considered this
possibility, we found vaccinating boys to be more attractive, but
Figure 3. Projected impact of vaccinating both pre-adolescent girls and boys at 71% coverage compared to increasing coverage to
90% for a girls-only program on non-cervical human papillomavirus (HPV)-16, -18 related cancers. Dotted lines represent the
theoretical maximum attributable fraction of HPV-16, -18 for each condition.
doi:10.1371/journal.pone.0089974.g003
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we also did not account for the better prognosis among HPV-
positive cancers compared to their HPV-negative counterparts,
potentially overestimating vaccine benefit. We modeled hetero-
sexual behavior while transmission among MSM was not explicitly
considered. Although the burden of disease estimates did reflect
cases among all individuals (including MSM), this omission likely
overestimated the level of herd immunity conferred to males in a
female-only vaccination program. Even so, we found that the herd
immunity benefits in the female-only HPV vaccination program
would have to be overestimated by more than 15% in order for the
cost per QALY gained to fall below $50,000. Norwegian sexual
behavior data suggest that the proportion of MSM is between
0.6% and 2.8% (depending on age) whereby more individuals
identify with bisexual behavior compared to exclusively being
homosexual, particularly prior to age 30, when the majority of
HPV transmission takes place (see File S1). While a small
proportion of herd immunity may be overestimated in our model,
bisexual behavior may continue to propagate herd immunity
benefits and the expected herd immunity reduction with at-most a
3% exclusively-male MSM population would be less than the
threshold of 15%.
We did not account for any level of vaccine cross-protection
related to non-vaccine types observed in clinical trials [50]. The
duration of cross-protection is uncertain, and the majority of male
HPV-related diseases are attributed to HPV-16 and -18, so the
inclusion of cross-protection is likely to be nominal in reducing the
burden of disease among males. Inclusion of cross-protection may
reinforce the argument for increasing female coverage rate,
however.
The quality and completeness of the Norwegian Cancer
Registry have been documented [51], but little research has been
done on the burden of HPV infection in Norway, particularly in
men, or more recent sexual mixing patterns by age and by sexual
activity. We used empirical data from one large city in Norway to
inform our bounds for HPV prevalence in Norway (Mari Nyga ˚rd,
personal communication), but there may be considerable geo-
graphic variation with respect to sexual behavior and HPV
prevalence. In order to fit the observed data, our calibrated
transmission probabilities may have been higher in order to fit a
high observed prevalence. Conversely, we did not allow for the
potential of cross-border behavior, which may overestimate herd
immunity, given vaccination rates among girls may not be as high
in other countries. Lastly, our understanding of the natural history
and HPV type attribution of non-cervical HPV-related diseases is
limited but growing; analyses can be revisited as new detection
methods and systematic reviews continue to define the natural
history and attributable fraction of HPV on associated cancers.
Conclusions
At Norway’s assumed HPV vaccine tender price, vaccinating
boys seems attractive and may warrant a change in the current
female-only vaccination policy. However, increasing coverage in
girls is uniformly more effective and cost-effective than expanding
vaccination coverage to boys and should be considered a priority.
Supporting Information
File S1 Supplementary appendix providing additional informa-
tion on model inputs, the Norwegian-specific calibration process,
and additional results.
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